Health · 2 views
Novel alpha radiopharmaceutical therapy shows promise in early-phase prostate cancer trial
A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a trial published in The…
Summary
A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a trial published in The Journal of Nuclear Medicine 's Late-Breaking Fast Track.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Needle-free Strep A vaccine triggers local and bodywide immune responses in miceContinue reading
- Low-carb diet high in saturated fat shows mixed effects on cholesterol in two-year trialContinue reading
- Congress Mulls Ways to Fix the Surprise Billing LawContinue reading
- Fenebrutinib May Curb Chronic Active Lesions in Multiple SclerosisContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow